Download Rescue Brochure

Our global network and decentralized operations model allows Pharm-Olam to quickly initiate sites in countries that typically have far higher rates of recruitment than the U.S. or Western Europe. Whether you need additional sites in an active country, sites in new countries, or want to hand over an ongoing study, Pharm-Olam can help you meet your enrollment needs while delivering quality data.

Pharm-Olam has a Rescue Start-Up Team which quickly analyzes options for enrollment including: additional countries, new sites within existing countries, and assessing active sites with potential for improvement. After assessment, the plan is initiated by specialists who work in parallel to achieve regulatory approval, site agreements and logistical requirements for the study.

Contact us for a free feasibility study to determine the best countries and sites for your study timelines.

Rescue Study Examples
Indication
Countries
Phase Sites Pts
Anemia (pediatric) Mexico, Poland, Russia, Serbia
IV
16
50
Asthma (pediatric) Poland
III
12
197
Breast Cancer (vaccine) Poland
II
4
60
Cellulitis Serbia
IV
4
48
Crohn's Disease Serbia
III
10
15
Crohn's Disease Hungary
II
11
58
Crohn's Disease Belarus, Bulgaria, Czech, Georgia, Poland, Romania, Russia, Ukraine
III
50
317
Crohn's Disease Hungary, Czech, Poland, Bulgaria
III
33
251
Crohn's Disease Russia, Serbia
III
3
58
Essential Thrombocythaemia Poland, Czech, Slovakia, Slovenia, Hungary, Ireland, Bulgaria, Romania, Belgium, Serbia, Spain, Portugal, France, Italy
III
22
180
Essential Thrombocythaemia UK, Ireland, Norway, Sweden, Denmark, Germany, Spain, Italy, France, Greece, Netherlands, Portugal, Finland
IV
146
3668
Head and Neck Cancer India, Ukraine, Russia, Croatia, Slovakia, Romania, Serbia
III
34
76
Head and Neck Cancer Czech, Lithuania, Estonia, Poland, Russia
III
15
139
Hepatitis B (vaccine) Czech, Hungary
III
10
181
Myocardial Infarction, Acute (stent) Latvia
II
3
36
NSCLC Australia, Belgium, Brazil, Bulgaria, Canada, Chile, Czech, France, Germany, Italy, Mexico, Poland, Romania, Russia, Spain, Ukraine, UK, USA
III
196
905
NSCLC Russia, Serbia
II
9
30
Pneumonia (HAP) Russia, Ukraine, Georgia, Belarus
III
24
197
Pneumonia (HAP and VAP) Latvia, Lithuania, Poland, Slovakia, Czech, Georgia, Ukraine, Mexico, Slovenia, Russia
III
55
141
Post Herpetic Neuralgia Czech, Slovakia, Poland, Bulgaria, Serbia
III
30
105
Prosthetic Joint Infection USA, UK
III
24
72
Rheumatoid Arthritis Serbia, Hungary, Bulgaria
II
10
98
Rheumatoid Arthritis Serbia
II
3
29
Rhinitis, Seasonal (pediatric) Poland
III
10
263
Systemic Lupus Erythematosus with renal disease Bulgaria, Romania, Ukraine, Serbia, Belarus, Georgia, USA
III
43
137
Tinea pedis Bulgaria
II
5
242
Ulcerative Colitis Poland
II
5
20
Urinary Retention Russia, Ukraine, Bulgaria
III
9
143
Urinary Retention Bulgaria, Ukraine
III
8
477

Letter from Sponsor of Head and Neck Cancer Rescue

Our company initiated a large global oncology clinical trial in 2006 with another global CRO (ie not POI). Recruitment was an ongoing challenge and by the end of 2006 we had only recruited a fraction of the patients expected to be enrolled by that time, and were having serious issues with the CRO working for us in Eastern Europe.

We originally brought on POI to provide a ‘rescue’ service for us in Eastern Europe to replace the CRO being utilized in those countries. The POI project manager was one of the best I have ever worked with in 20 years of trials. She, and the POI project team, orchestrated the rescue and made a difficult transition go very smoothly without any significant impact on the study operations and completed this within a short period of time.

We were so impressed with the quality, efficiency and professionalism of this group in Eastern Europe, that we decided to also bring POI on board to cover India. Again, we were provided with a project manger of excellent quality who got the sites selected and up and running within a couple of months.

POI surpassed recruitment expectations within the countries they managed for us. They were easy to work with, flexible in meeting our reporting requirements and worked closely with the sites to ensure recruitment goals were met, patient care and the quality of the data being collected was excellent. We then utilized POI for a phase I dose-escalation study in 3 countries in Eastern Europe and had the same positive experience working with that team as we did our global trial.

I have worked with many large and small CROs over the years and would highly recommend POI for any project of any complexity.

Regards,
Chief Operating Officer and VP of Clinical Operations


Company Overview
| Services |  Operations   |   Case Studies   |   Careers  |  Investigators  |   Contact

© 1994 - 2010 Pharm-Olam International. All Rights Reserved.